Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

An Overview of the Role of Microbiomes in the Severity of Colorectal Cancer

Document Type : Review Article

Author

Ramesh Ranjbar

Department of Genetics, Faculty of Basic Sciences, Shahrekord Islamic Azad University, Shahrekord, Iran

https://doi.org/10.22034/pmj.2024.715091
Abstract
Microbiome means microbes coexisting with the host, regardless of the species, in a part of the body of an organism called microbiome. Nowadays, changes in gut microbiota are considered as a potential therapeutic approach for the prevention or treatment of colorectal cancer (CRC).Studies have shown that dietary habits and lifestyle play a role in modulating the gut microbiota.
Intestinal microbiota plays a role in converting food components into oncometabolites. Some studies showed that Shigella, Citrobacter and Salmonella bacteria are more abundant in the early stages of cancer compared to healthy people. The aim of this study is to review the role of microbiomes in the development of colorectal cancer and the metabolites produced by microbiomes in the development of colorectal cancer.

Keywords

Microbiome
Colorectal cancer
Genetics
Environmental factors
  1. Sánchez-Alcoholado, L., et al., The role of the gut microbiome in colorectal cancer development and therapy response. Cancers, 2020. 12(6): p. 1406.
  2. Rooks, M.G. and W.S. Garrett, Gut microbiota, metabolites and host immunity. Nature reviews immunology, 2016. 16(6): p. 341-352.
  3. Benson, A.K., et al., Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proceedings of the National Academy of Sciences, 2010. 107(44): p. 18933-18938.
  4. Costello, E.K., et al., Bacterial community variation in human body habitats across space and time. science, 2009. 326(5960): p. 1694-1697.
  5. Piri Gharaghie T, Doosti A, Mirzaei SA. Prevalence and antibiotic resistance pattern of Acinetobacter spp. infections in Shahrekord medical centers. Developmental Biology. 2021 Nov 22;13(4):35-46.
  6. Bhat, M.I. and R. Kapila, Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. Nutrition reviews, 2017. 75(5): p. 374-389.
  7. Chattopadhyay, I., et al., Exploring the role of gut microbiome in colon cancer. Applied biochemistry and biotechnology, 2021. 193: p. 1780-1799.
  8. Costello, E.K., et al., The application of ecological theory toward an understanding of the human microbiome. Science, 2012. 336(6086): p. 1255-1262.
  9. Wieczorska, K., M. Stolarek, and R. Stec, The role of the gut microbiome in colorectal cancer: where are we? Where are we going? Clinical Colorectal Cancer, 2020. 19(1): p. 5-12.
  10. Dzutsev, A., et al., The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. European journal of immunology, 2015. 45(1): p. 17-31.
  11. Piri Gharaghie T, Hajimohammadi S. Comparison of anti-candida effects of aqueous, ethanolic extracts and essential oil of E. angustifolia with fluconazole on the growth of clinical strains of Candida. New Cellular and Molecular Biotechnology Journal. 2021 Jul 10;11(43):25-38.
  12. Rubinstein, M.R., et al., Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell host & microbe, 2013. 14(2): p. 195-206.
  13. Taghiloo S, Ghajari G, Zand Z, Kabiri‐Samani S, Kabiri H, Rajaei N, Piri‐Gharaghie T. Designing alginate/chitosan nanoparticles containing echinacea angustifolia: a novel candidate for combating multidrug‐resistant staphylococcus aureus. Chemistry & Biodiversity. 2023 Jul;20(7):e202201008.
  14. Moskal, A., et al., Main nutrient patterns and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study. British journal of cancer, 2016. 115(11): p. 1430-1440.
  15. Piri Gharaghie Tohid, DOOSTI ABBAS, MIRZAEI SEYED ABBAS. Detection of T6SS secretory system and membrane purine involved in antibiotic resistance in multidrug-resistant Acinetobacter baumannii isolates. JOURNAL OF MICROBIAL WORLD[Internet]. 2021;14(1 (46) ):47-58. Available from: https://sid.ir/paper/999438/en
  16. Gharaghie TP, Beiranvand S, Abbas Doosti AH, Ghadiri SH. A review of the epidemiology and clinical signs of SARS-COV-2. NCMB J. 2020;11(41):103-20.
  17. Gao, R., et al., Gut microbiota and colorectal cancer. European Journal of Clinical Microbiology & Infectious Diseases, 2017. 36: p. 757-769.
  18. Saus, E., et al., Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. Molecular aspects of medicine, 2019. 69: p. 93-106.
  19. Ambalam, P., et al., Probiotics, prebiotics and colorectal cancer prevention. Best practice & research Clinical gastroenterology, 2016. 30(1): p. 119-131.
  20. Albenberg, L., et al., Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology, 2014. 147(5): p. 1055-1063. e8.
  21. Ghourchian H, Pecho RD, Karimi-Dehkordi M, Mazandarani A, Ghajari G, Piri-Gharaghie T. Novel niosome-encapsulated 2, 5-diketopiperazine (BHPPD): Synthesis, formulation, and anti-breast cancer activity. Applied Biochemistry and Biotechnology. 2024 Jun;196(6):3126-47.
  22. Kahouli, I., C. Tomaro-Duchesneau, and S. Prakash, Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal of medical microbiology, 2013. 62(8): p. 1107-1123.
  23. Zarinnezhad A, Shahhoseini MH, Piri Gharaghie T. Evaluating the relative frequency of fungal infections in the serum of patients with multiple sclerosis and healthy subjects using PCR. Journal of Microbial Biology. 2021 Mar 21;10(37):37-50.
  24. Peterson, D.A., et al., Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell host & microbe, 2008. 3(6): p. 417-427.
  25. Owyang, C. and G.D. Wu, The gut microbiome in health and disease. Gastroenterology, 2014. 146(6): p. 1433-1436.
  26. Goubet, A.-G., et al., The impact of the intestinal microbiota in therapeutic responses against cancer. Comptes rendus biologies, 2018. 341(5): p. 284-289.
  27. Yang, Y. and C. Jobin, Novel insights into microbiome in colitis and colorectal cancer. Current opinion in gastroenterology, 2017. 33(6): p. 422-427.
  28. Plotnikoff, G.A., Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment. Global Advances in Health and Medicine, 2014. 3(3): p. 33-43.
  29. Raay, T.V. and E. Allen-Vercoe, Microbial interactions and interventions in colorectal cancer. Bugs as Drugs: Therapeutic Microbes for the Prevention and Treatment of Disease, 2018: p. 99-130.
  30. Chang, P.V., et al., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings of the National Academy of Sciences, 2014. 111(6): p. 2247-2252.
  31. Macfarlane, G.T. and S. Macfarlane, Bacteria, colonic fermentation, and gastrointestinal health. Journal of AOAC International, 2012. 95(1): p. 50-60.
  32. Calmels, S., et al., Screening of microorganisms for nitrosation catalysis at pH 7 and kinetic studies on nitrosamine formation from secondary amines by E. coli strains. Carcinogenesis, 1985. 6(6): p. 911-915.
  33. Sabit, H., E. Cevik, and H. Tombuloglu, Colorectal cancer: The epigenetic role of microbiome. World journal of clinical cases, 2019. 7(22): p. 3683.
  34. Cui, H., et al., Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon. Frontiers in pharmacology, 2018. 9: p. 370842.
  35. Khare, S., et al., Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer research, 2003. 63(13): p. 3517-3523.
  36. Everard, A., et al., Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the national academy of sciences, 2013. 110(22): p. 9066-9071.
  37. Sears, C.L. and D.M. Pardoll, Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. Journal of Infectious Diseases, 2011. 203(3): p. 306-311.
  38. Tjalsma, H., et al., A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects. Nature Reviews Microbiology, 2012. 10(8): p. 575-582.
  39. Attene-Ramos, M.S., et al., Evidence that hydrogen sulfide is a genotoxic agent. Molecular Cancer Research, 2006. 4(1): p. 9-14.
  40. Gao, R., et al., Mucosa-associated microbiota signature in colorectal cancer. European journal of clinical microbiology & infectious diseases, 2017. 36(11): p. 2073-2083.
  41. DuPont, H.L., Bacterial diarrhea. New England Journal of Medicine, 2009. 361(16): p. 1560-1569.
  42. Buc, E., et al., High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PloS one, 2013. 8(2): p. e56964.
  43. Liang, Q., et al., Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clinical Cancer Research, 2017. 23(8): p. 2061-2070.
  44. Tsoi, H., et al., Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology, 2017. 152(6): p. 1419-1433. e5.
  45. Dejea, C.M. and C.L. Sears, Do biofilms confer a pro-carcinogenic state? Gut microbes, 2016. 7(1): p. 54-57.
  46. Papastergiou, V., S. Karatapanis, and S.D. Georgopoulos, Helicobacter pylori and colorectal neoplasia: Is there a causal link? World journal of gastroenterology, 2016. 22(2): p. 649.
  47. Zhang, J.-W., et al., Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. The American journal of the medical sciences, 2012. 343(3): p. 199-205.
  48. Boleij, A., et al., Bacterial responses to a simulated colon tumor microenvironment. Molecular & Cellular Proteomics, 2012. 11(10): p. 851-862.
  49. Liu, Z., et al., Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial. BMC gastroenterology, 2015. 15: p. 1-14.
  50. Molska, M. and J. Reguła, Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients, 2019. 11(10): p. 2453.
  51. Dahmus, J.D., et al., The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. Journal of gastrointestinal oncology, 2018. 9(4): p. 769.
  52. Whitehead, R., G. Young, and P. Bhathal, Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). Gut, 1986. 27(12): p. 1457-1463.
  53. Bashir, A., et al., Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. European Journal of Cancer Prevention, 2015. 24(5): p. 373-385.
  54. Bozkurt, H.S., E.M. Quigley, and B. Kara, Bifidobacterium animalis subspecies lactis engineered to produce mycosporin-like amino acids in colorectal cancer prevention. SAGE open medicine, 2019. 7: p. 2050312119825784.
  55. Attene-Ramos, M.S., et al., Hydrogen sulfide induces direct radical-associated DNA damage. Molecular cancer research, 2007. 5(5): p. 455-459.
  56. Pithva, S.P., et al., Antigenotoxic and antimutagenic activities of probiotic Lactobacillus rhamnosus Vc against N-methyl-N′-nitro-N-nitrosoguanidine. Nutrition and cancer, 2015. 67(7): p. 1142-1150.
  57. Lattimer, J.M. and M.D. Haub, Effects of dietary fiber and its components on metabolic health. Nutrients, 2010. 2(12): p. 1266-1289.
  58. Bingham, S.A., et al., Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. The lancet, 2003. 361(9368): p. 1496-1501.
  59. Deehan, E.C., et al., Precision microbiome modulation with discrete dietary fiber structures directs short-chain fatty acid production. Cell host & microbe, 2020. 27(3): p. 389-404. e6.
  60. Chen, H.-M., et al., Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. The American journal of clinical nutrition, 2013. 97(5): p. 1044-1052.
  61. Gensollen, T., et al., How colonization by microbiota in early life shapes the immune system. Science, 2016. 352(6285): p. 539-544.
  62. Watson, H., et al., A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut, 2018. 67(11): p. 1974-1983.
  63. Torre, L.A., et al., Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015. 65(2): p. 87-108.
  64. Fleming, M., et al., Colorectal carcinoma: Pathologic aspects. Journal of gastrointestinal oncology, 2012. 3(3): p. 153.
  65. Merchant, N.B., et al., Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery, 2005. 138(3): p. 415-421.
  66. Culpepper, T., et al., Associations between diet, gut microbiota and markers of CRC risk. Cancer & Metabolism, 2014. 2: p. 1-1.
  67. Wu, S., et al., A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature medicine, 2009. 15(9): p. 1016-1022.
  68. Goodwin, A.C., et al., Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proceedings of the National Academy of Sciences, 2011. 108(37): p. 15354-15359.

 

Personalized and Precision Medicine Journal
Volume 9, Issue 34
Original article
Summer 2024
Pages 20-26

  • Receive Date 21 April 2024
  • Revise Date 15 June 2024
  • Accept Date 29 August 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us